To reach the next value inflection
LicenseRx asset brief
Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays
Probability of Success
25% · grade C · Medium data confidence
Model PoS 25% (grade C, medium data confidence). Strongest signals: Data maturity, Modality feasibility. Biggest drag: IP position.
Data maturity (22%)
63
Preclinical; human data, clinical reference.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
80
Diagnostic/biomarker -- can monetize via service before full approval.
Indication pull (14%)
70
Infectious Disease -- active buyer appetite.
Competitive whitespace (12%)
86
Under-served segment; multi-modal differentiation.
Translational evidence (12%)
62
Public evidence mentions: clinical, human.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →